

**CURRICULUM VITAE****Michael LeBlanc, Ph.D.****1. Biographical Information**

SWOG (Southwest Oncology Group) Statistical Center  
1100 Fairview Avenue, M3-C102  
Seattle, WA 98109-1024  
Phone: (206) 667-4623

**2. Education:**

Simon Fraser University, B.Sc. (Mathematics), 1983  
University of Waterloo, M.Math. (Statistics), 1984  
University of Washington, Ph.D. (Biostatistics), 1989

**3. Licensure:** Not Applicable**4. Professional Positions**

Post-doctoral Fellow, University of Washington and Fred Hutchinson Cancer Research Center, 1989-90.  
Assistant Professor, Department of Preventive Medicine and Biostatistics, University of Toronto, 1990-94.  
Associate Member of the School of Graduate Studies, University of Toronto, 1991-94.  
Assistant Professor, Department of Statistics, University of Toronto (cross appointment), 1992-94.  
Assistant Member, Fred Hutchinson Cancer Research Center, 1995-96.  
Research Assistant Professor, Department of Biostatistics, University of Washington, 1995-97.  
Associate Member, Fred Hutchinson Cancer Research Center, 1996-2001.  
Research Associate Professor, Department of Biostatistics, University of Washington, 1997-2002.  
Member, Fred Hutchinson Cancer Research Center, 2001- present.  
Research Professor, Department of Biostatistics, University of Washington, 2002-present.  
Group Statistician and Director of Statistical Center, Southwest Oncology Group, 2012-present.

**5. Honors, Awards, Scholarships**

Simon Fraser University Open Scholarships, 1978-81.  
School of Public Health Tuition Scholarship, 1986-88.  
Donovan Thompson Award for outstanding achievement in the qualifying examinations of the Biostatistics program, University of Washington, 1986.  
Natural Science and Engineering Research Council Postgraduate Scholarship, 1985-88.  
Best Paper in the Canadian Journal of Statistics, 1995.

**6. Professional Activities (outside of the UW)**Referee:

Annals of Statistics,  
Biometrics,  
Biometrika,  
Blood,  
Canadian Journal of Statistics,  
Cancer and Epidemiology,  
Central European Journal of Biology,  
Clinical Cancer Research,

Computational Statistics and Data Analysis,  
 Data Mining and Knowledge Discovery,  
 Genetic Epidemiology,  
 Head and Neck,  
 Journal of the American Statistical Association,  
 Journal of Artificial Intelligence Research,  
 Journal of Clinical Oncology,  
 Journal of Computational and Graphical Statistics,  
 Journal of the Royal Statistical Society,  
 Journal of the National Cancer Institute,  
 Journal of Physiological Genomics,  
 Medical and Pediatric Oncology,  
 Proceedings of the National Academy of Sciences.  
 Risk Analysis,  
 Sankhya,  
 Statistics in Medicine

Reviewer:

Canadian Society of Epidemiology and Biostatistics,  
 Chapman Hall,  
 Mathematics Sciences Program—American Mathematical Society,  
 Medical Research Council of Canada,  
 National Cancer Institute, NIH,  
 Natural Sciences and Engineering Research Council of Canada,  
 Springer-Verlag,

Editor:

Section Editor (Biostatistics), AACR: Clinical Cancer Research, 2010-2014.  
 Guest Editor, Computational Statistics and Data Analysis, Special issue: Computational Statistics for Clinical Research, 2011.  
 Associate Editor, Sankhya, 2011-present.  
 Associate Editor, Clinical Trials, 2013-present

Other Professional Activities:

Research Associate, Province of British Columbia, Ministry of Human Resources, Vancouver, British Columbia, 1981-82.  
 Research Associate, Province of British Columbia, Ministry of Human Resources, Vancouver, British Columbia, 1984-85.  
 Research Assistant, Fred Hutchinson Cancer Research Center, Seattle, Washington, 1988-89.  
 Member Research Services Unit, University of Toronto, Department of Preventive Medicine and Biostatistics, (approximately 25 projects per year), 1990-94.  
 Member, Head and Neck Intergroup Correlative Science Committee, (NCI), 1997-2006.  
 Member, Independent Data Monitoring Committees for studies in head and neck cancer study (TAX322) and gastric cancer study (TAX325), (Aventis), 1998-2004.  
 Consultant, (formerly Mathsoft) Insightful Corporation, 1998-2005.  
 Consultant, Arkansas Cancer Research Center, 1999.  
 FHCRC Faculty Representative, Federal Demonstration Partnership, (A cooperative initiative among federal agencies and research institutions), 1999-2005.  
 Member, Statistical Committee, American Joint Committee on Cancer (American Cancer Society and American College of Surgeons), 2000-2003.  
 Member, Independent Data Monitoring Committee for studies for MD Anderson Cancer Center and Statistics Collaborative, Inc., 2003-2010.  
 Member, Scientific Program Committee of the American Society of Clinical Oncology, 2005-2007.  
 Member, NCI Head and Neck Cancer Steering Committee, 2006-2007.

Member, Independent Data Monitoring Committee, J&J Oncology, 2006-2007.  
 Member, Statistical and Lymphoma Committee, American Joint Committee on Cancer (American Cancer Society and American College of Surgeons), 2006-present.  
 Member, NCI Head & Neck Steering Committee, Section: Previously Untreated Patients, 2007-2010.  
 Member, Independent Data Monitoring Committee, Sanofi-aventis, 2007-2010.  
 Member, Data Monitoring Committee for the North Central Cancer Treatment Group (NCCTG) 2008-2011.  
 Member, NCI Clinical Trials Design Task Force (Phase II), 2008-2011.  
 Member, Molecular Modeler Working Group, American Joint Committee on Cancer, 2009-present.  
 Ad Hoc member, Special Emphasis Panel; NCI Epidemiology, Prevention Control & Population Sciences P01 Review Committee, 2007-2010.  
 Member, Program Assessment of Clinical Cancer Tests (PACCT) NCI working group, 2009- present.  
 Member, Independent Data Monitoring Committee, Lilly Oncology, 2010-2014.  
 Member, NCI Lymphoma Steering Committee, 2010-present.  
 Member, NCI Imaging Steering Committee, 2011-present.  
 Co-Chair, NCI Clinical Trials Design Task Force (Phase II), 2011-present.  
 Ad Hoc member, Special Emphasis Panel: Clinical Assay Development Program, NCI, 2011.  
 Member, NCI Steering Committee Working Group, 2011- present  
 Member, Advisory Panel for the Group Banking Navigation System 2012-present.  
 Member, Clinical Trials and Translational Research Advisory Committee (CTAC), 2015-present.  
 Member, CTAC Clinical Trials Working Group, 2015-present.

## 7. Bibliography (Numbered)

### a) Refereed Research Articles

1. Albain K, Crowley J, **LeBlanc M**, Livingston R. Determinants of improved outcome for patients with small cell lung cancer: An analysis of the 2580 patient Southwest Oncology Group data base. *J Clin Oncol* 8(9):1563-1574, 1990.
2. Albain K, Crowley J, **LeBlanc M**, Livingston R. Survival determinants in extensive stage non-small cell lung cancer: The Southwest Oncology Group experience. *J Clin Oncol* 9(9):1618-1626, 1991.
3. Tibshirani R, **LeBlanc M**. A strategy for binary classification and description. *Journal of Computational and Graphical Statistics* 1:3-20, 1992.
4. **LeBlanc M**, Crowley J. Relative risk regression trees for censored survival data. *Biometrics* 48:411-425, 1992.
5. Albain K, Green S, **LeBlanc M**, et al. Proportional hazards and recursive partitioning and amalgamation analysis of the Southwest Oncology Group node-positive adjuvant CMFVP breast data base. *Breast Cancer Res Treat* 22(3):273-284, 1992.
6. Sagman U, **LeBlanc M**, Maki E, Feld R. Verification of a multicenter prognostic model for small cell lung carcinoma. (Abstract), *American Association of Clinical Oncology* 12:337, 1993.
7. **LeBlanc M**, Crowley J. Survival trees by goodness of split. *JASA* 88:457-467, 1993.
8. Colgan T, Pendergest D, **LeBlanc M**. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues. *Hum Pathol* 24(10):1073-1077, 1993.
9. **LeBlanc M**, Tibshirani R. Adaptive principal surfaces. *JASA* 89:54-64, 1994.
10. **LeBlanc M**, Crowley J. Semi-parametric regression functionals. *JASA* 90:95-105, 1995.
11. Arnold J, Rohan T, Howe G, **LeBlanc M**. Reproducibility and validity of a food frequency questionnaire designed for use in girls 7 to 12 years. *Annals of Epidemiology* 5(5):369-377, 1995.
12. Tammemagi M, Frank J, **LeBlanc M**, Artsob H. Intra- and inter-laboratory reproducibility of an ELISA serologic test for lyme disease. *Canadian Journal of Infectious Diseases* 6(2):90-95, 1995.
13. **LeBlanc M**. An adaptive expansion method for regression. *Statistica Sinica* 5(2):737-748, 1995.

14. Tammemagi M, Frank J, **LeBlanc M**, et al. Methodological issues in assessing reproducibility - A comparative study of various indices of reproducibility applied to repeat ELISA serologic tests for lyme disease. *J Clin Epidemiol* 48(9):1123-1132, 1995.
15. **LeBlanc M**, Crowley J. Step-function covariate effects in the proportional hazards model. *Canadian Journal of Statistics* 23(2):109-129, 1995.
16. Strathdee S, Frank J, McLaughlin J, **LeBlanc M**, Major C, O'Shaughnessy M, Reed S. Quantitative measure of HIV-specific antibodies predict progression to AIDs. *J Infect Dis* 172(5):1375-1379, 1995.
17. **LeBlanc M**, Tibshirani R. Combining estimates in regression and classification. *JASA* 91:1641-1650, 1996.
18. Albain K, Crowley J, **LeBlanc M**, Livingston R. Survival determinants in extensive-stage non-small-cell lung cancer. The Southwest Oncology Group experience. *Classic Papers and Current Comments* 2(1):135-144, 1997.
19. Kasendra M, Johnson I, Casavera L, **LeBlanc M**. Correlates of condom use in the young adult population in Ontario. *Canadian Journal of Public Health* 88(12):280-285, 1997.
20. LeBlanc M. Restricted polynomial regression. *Computational Statistics and Data Analysis* 24:153-168, 1997.
21. Stiff P, Dahlberg S, Forman S, McCall A, Horning S, Nademanee A, Blume K, **LeBlanc M**, Fisher R. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens. *J Clin Oncol* 16(1):48-57, 1998.
22. Press OW, **LeBlanc M**, O'Rourke TJ, et al. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. *J Clin Oncol* 16(2):574-578, 1998.
23. Al-Sarraf M, **LeBlanc M**, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. *J Clin Oncol* 16(4):1310-1317, 1998.
24. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, **LeBlanc M**, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. *New England Journal of Medicine* 339(10):21-26, 1998.
25. **LeBlanc M**, Tibshirani R. Monotone shrinkage trees. *Journal of Computational and Graphical Statistics* 7(4):417-433, 1998.
26. Moore F Jr., Brown T, **LeBlanc M**, Miller T, McClure S, Fisher F. Phase II trial of menogaril Non-Hodgkin's lymphoma: A Southwest Oncology Group Study. *Investigational New Drugs* 17(2):169-172, 1999.
27. Al-Sarraf M, **LeBlanc M**, Giri PGS, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. *Classic Papers & Current Comments* 4(3):649-656, 1999.
28. **LeBlanc M**. Resampling quantile estimating functions and density estimation. *Computational Statistics and Data Analysis* 29:163-176, 1999.
29. **LeBlanc M**, Crowley J. Using the bootstrap for estimation in group sequential design: An application to a clinical trial for nasopharyngeal cancer. *Statistics in Medicine* 18:2635-2644, 1999.
30. Liu PY, **LeBlanc M**, Desai M. False positive rates of randomized phase II designs. *Controlled Clinical Trials* 20(4):343-352, 1999.
31. **LeBlanc M**, Crowley J. Adaptive regression splines in the Cox Model. *Biometrics* 55(1):204-213, 1999.
32. Fisher RI, Dana BW, **LeBlanc M**, Kjeldsberg C, Unger J, Lichter A, Miller T. Alpha-Interferon consolidation following intensive chemotherapy does not prolong the progression-free survival of patients with low grade Non-Hodgkin's lymphoma: Results of SWOG-8809, A Randomized Phase III Study. *J Clin Oncol* 18:2010-2016, 2000.
33. Taylor CW, **LeBlanc M**, Fisher RI, Moore DF Sr., Roach RW, Elias L, Miller TP. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: A Southwest Oncology Group trial. *Anticancer Drugs* 11(9):695-700, 2000.

34. Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA Jr., Mills GM, Balcerzak SP, Varterasian M, **LeBlanc M**, Fisher RI. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group Study. *J Clin Oncol* 19:750-755, 2001.
35. Kooperberg C, Ruczinski I, **LeBlanc M**, Hsu L. Sequence analysis using logic regression. *Genetic Epidemiology* 21:626-631, 2001.
36. Press O, **LeBlanc M**, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. A phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine and subtotal lymphoid irradiation for stage IA-IIA Hodgkin's disease (SWOG 9133, CALGB 9391). *J Clin Oncol* 19:4238-4244, 2001.
37. Faraggi D, **LeBlanc M**, Crowley J. Understanding neural networks using regression trees: an application to multiple myeloma survival data. *Stat in Med* 20:2965-2976, 2001.
38. Kooperberg C, Ruczinski I, **LeBlanc M**, Hsu L. Sequence analysis using logic regression. *Genet Epidemiol* 21(Suppl 1):626-631, 2001.
39. **LeBlanc M**, Jacobson J, Crowley J. Partitioning and peeling for constructing prognostic groups. *Stat Methods Med Res* 11:247-274, 2002.
40. Abdollell M, **LeBlanc M**, Stephens D, Harrison RV. Binary partitioning for continuous longitudinal data: categorizing a prognostic variable. *Stat in Med* 21:3395-3409, 2002.
41. Kooperberg C, Sipione S, **LeBlanc M**, Strand A, Cattaneo E, Olson JM. Evaluating test statistics to select interesting genes in microarray experiments. *Hum Mol Genet* 11(19):1-10, 2002.
42. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *N Engl J Med* 346(25):1937-1947, 2002.
43. Blayney DW, **LeBlanc ML**, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). *J Clin Oncol* 21(13):2466-2473, 2003.
44. **LeBlanc M**, Kooperberg C, Grogan TM, Miller TP. Directed indices for exploring gene expression data. *Bioinformatics* 19(6):686-693, 2003.
45. The Lymphoma/Leukemia Molecular Profiling Project. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. *Cancer Cell* 3:185-197, 2003.
46. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, **LeBlanc M**, Gaynor ER, Rivkin SE, Fisher RI. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. *Blood* 102(5):1606-1612, 2003.
47. Ditzler S, Stoeck J, **LeBlanc M**, Kooperberg C, Hansen S, Coppin L, Olson JM. A rapid neurobehavioral assessment reveals that FK506 delays symptom onset in R6/2 Huntington's disease mice. *Preclinica* 1(3):115-126, 2003.
48. Stiff PJ, Unger JM, Forman SJ, McCall AR, **LeBlanc M**, Nademanee AP, Bolwell BJ, Fisher RI. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. *Biol Blood Marrow Transplant* 9:529-539, 2003.
49. Ruczinski I, Kooperberg C, **LeBlanc M**. Logic regression. *J Comput Graph Stat* 12(3):475-511, 2003.
50. Unger JM, **LeBlanc M**, Crowley JJ, et al. Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: The Karnofsky Memorial Lecture. *J Clin Oncol* 21(23s):246-252, 2003.
51. Rosenwald AR, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, **LeBlanc M**, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med* 198(6):851-862, 2003.

52. Ruczinski I, Kooperberg C, **LeBlanc ML**. Exploring interactions in high-dimensional genomic data: an overview of logic regression, with applications. *Journal of Multivariate Analysis* 90:178-195, 2004.
53. Rimsza LM, Roberts RA, Miller TP, Unger JM, **LeBlanc M**, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood* 103(11):4251-4258, 2004.
54. Unger JM, **LeBlanc M**, Thompson IM, Coltman CA Jr. The person-years saved model and other methodologies for assessing the population impact of cancer-prevention strategies. *Urol Oncol* 22:362-368, 2004.
55. Nason M, Emerson S, **LeBlanc M**. CARTscans: a tool for visualizing complex models. *J Comput Graph Stat* 13(4):807-825, 2004.
56. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haïoun C, **LeBlanc M**, et al. Follicular Lymphoma International Prognostic Index. *Blood* 104(5):1258-1265, 2004.
57. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Wing CC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, **LeBlanc M**, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. *N Engl J Med* 351(21):2159-2169, 2004.
58. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, **LeBlanc M**, Eary J, Krohn K. FDG-PET predicts local disease control for head and neck squamous cell cancer. *Arch Otolaryngol Head Neck Surg* 130:1361-1367, 2004.
59. Urba SG, Moon J, Shankar Giri PG, Adelstein DJ, Hanna E, Yoo GH, **LeBlanc M**, Ensley JF, Schuller DE. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group trial. *J Clin Oncol* 23(1):88-95, 2005.
60. Unger JM, Thompson IM Jr, **LeBlanc M**, Crowley JJ, Goodman PJ, Ford LG, Coltman CA Jr. Estimated impact of the Prostate Cancer Prevention Trial on population mortality. *Cancer* 103(7):1375-1380, 2005.
61. **LeBlanc M**, Moon J, Crowley J. Adaptive risk group refinement. *Biometrics* 61:370-378, 2005.
62. Fisher RI, **LeBlanc M**, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. *J Clin Oncol* 23(33):8447-8452, 2005.
63. Schwartz DL, Ford E, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellyn B, Mattes D, Meyer J, Phillips M, **LeBlanc M**, et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. *Int J Radiat Oncol Biol Phys* 61(1):129-136, 2005.
64. Schwartz DL, Ford EC, Rajendran J, Yueh B, Coltrera MD, Virgin J, Anzai Y, Haynor D, Lewellen B, Mattes D, Kinahan P, Meyer J, Phillips M, **LeBlanc M**, et al. FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. *Head Neck* 27(6):478-487, 2005.
65. **LeBlanc M**, Moon J, Kooperberg C. Extreme regression. *Biostatistics* 7(1):71-84, 2006.
66. Adelstein DJ, **LeBlanc M**. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? *J Clin Oncol* 24(17):2624-2628, 2006.
67. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, **LeBlanc M**, Fisher RI. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911. *J Clin Oncol* 24(25):4143-4149, 2006.
68. Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I, Zettl A, Rosenwald A, Ott G, Muller-Hermelink HK, Delabie J, Fisher RI, Unger JM, **LeBlanc M**, et al. Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. *Blood* 107(3):1101-1107, 2006.

69. Dai JY, Ruczinski I, **LeBlanc M**, Kooperberg C. Imputation methods to improve inference in SNP associated studies. *Genet Epidemiol*, 30:690-702, 2006.
70. Fan J, Su XG, Levine R, Nunn M, **LeBlanc M**. Trees for correlated survival data by goodness of split, with applications to tooth prognosis. *J Am Stat Assoc* 101(475):959-967, 2006.
71. Agrawal A, Moon J, Davis RK, Sakr WA, Giri SPG, Valentino J, **LeBlanc M**, Truelson JM, Yoo GH, Ensley JF, Schuller DE. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in Stage I, II and III squamous cell carcinoma of the supraglottic larynx. *Arch Otolaryngol Head Neck Surg* 133(10):1044-1050, 2007.
72. Roberts RA, Sabalos CM, **LeBlanc ML**, Martel RR, Frutiger YM, Unger JM, et al. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. *Lab Invest* 87:979-997, 2007.
73. Goldman B, **LeBlanc M**, Crowley J. Interim futility analysis with intermediate endpoints. *Clin Trials* 5:14-22, 2008. PMID: 18283075
74. Thompson JA, Fisher RI, **LeBlanc M**, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). *Blood* 111(8):4048-4054, 2008. PMID: 18256325. PMCID: PMC2288718
75. Kooperberg C, **LeBlanc M**. Increasing the power of identifying gene X gene interactions in genome-wide association studies. *Gen Epidemiol* 32:255-263, 2008. PMID: 18200600
76. Swinnen LD, **LeBlanc M**, Grogan TM, Gordon LI, Stiff PJ, Miller AM, Kasamon Y, Miller TP, Fisher RI. Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. *Clin Transplant* 86(2):215-222, 2008. PMID: 18645482
77. Persky DO, Unger JM, Spier CM, Stea B, **LeBlanc M**, McCarty MJ, Rimsza LM, Fisher RI, Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. *J Clin Oncol* 26(14):2258-2263, 2008. PMID: 18413640
78. Hoering A, **LeBlanc M**, Crowley JJ. Randomized Phase III clinical trial designs for targeted agents. *Clin Cancer Res* 14(14):4358-4367, 2008. PMID: 18628448. PMCID: PMC2569946
79. Rimsza LM, **LeBlanc ML**, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM, Campo E, Rosenwald A, Connors JM, Sehn LH, Johnson N, Gascoyne RD. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. *Blood* 112(8):3425-3433, 2008. PMID: 18544678
80. Dai J, **LeBlanc M**, Kooperberg C. Semiparametric estimation exploiting covariate independence in two-phase randomized trials. *Biometrics* 65(1):178-187, 2009. PMID: 18479485; PMCID: PMC2892338
81. Bernstein SH, Unger JM, **LeBlanc M**, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516--the Southwest Oncology Group. *J Clin Oncol* 27(1):114-119, 2009. PMID: 19047289
82. Rubenstein L, Crowley J, Ivy P, **LeBlanc M**, Sargent D. Randomized Phase II designs. *Clin Cancer Res* 15(6):1883-1890, 2009. PMID: 19276275; PMCID: PMC3774021
83. Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, **LeBlanc M**, Fisher RI, Miller TP. A Phase III trial of single agent bevacizumab in patients with relapsed, aggressive Non-Hodgkin lymphoma: Southwest Oncology Group study S0108. *Leuk Lymphoma* 50(5):728-735, 2009. PMID: 19373598; PMCID: PMC3532923
84. **LeBlanc M**, Rankin C, Crowley J. Multiple histology Phase II trials. *Clin Cancer Res* 15(13):4256-4262, 2009. PMID: 19549777
85. **LeBlanc M**, Kooperberg C. Adaptively weighted association statistics. *Gen Epidemiol* 33(5):442-452, 2009. PMID: 19170133; PMCID: PMC3571103; PMCID: PMC3571103
86. Yoo GH, Moon J, **LeBlanc M**, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J, Wolf G. A Phase II trial of surgery with perioperative INGN 201(Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral

- cavity, oropharynx, hypopharynx and larynx. *Arch Otolaryngol Head Neck Surg* 135(9):869-874, 2009. PMID: 19770418; PMCID: PMC3098124
87. Dai JY, **LeBlanc M**, Smith NL, Psaty B, Kooperberg C. SHARE: an adaptive algorithm to select the most informative set of SNPs for candidate genetic association. *Biostatistics* 10(4):680-693, 2009. PMID: 19605740, PMCID: PMC2742496
  88. Kooperberg C, **LeBlanc M**, Dai JY, Rajapakse I. Structures and assumptions: strategies to harness gene x gene and gene x environment interactions in GWAS. *Stat Sci* 24(4):472-488, 2009. PMID: 20640184, PMCID: PMC2904990
  89. Seymour L, Ivy PS, Sargent D, Spriggs D, Baker L, Rubenstein L, Ratain MJ, **LeBlanc M**, Stewart D, Crowley J, Groshen S, Humphrey JS, West P, Berry D. The design of Phase II clinical trials testing cancer therapeutics: consensus recommendations from the Clinical Design Task Force of the National Cancer Institute Investigational Drug Steering Committee. *Clin Cancer Res* 16(6):1764-1769, 2010. PMCID: PMC2840069
  90. Williamson SK, Moon J, Huang CH, Guaglianone PP, **LeBlanc M**, Wolf GT, Urba SG. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0420. *J Clin Oncol* 28(20):3330-3335, 2010. PMID: 20498388; PMCID: PMC2903329
  91. Sweetenham JW, Goldman B, **LeBlanc ML**, Cook JR, Tubbs RR, Press OW, Maloney DG, Fisher RI, Rimsza LM, Brazier RM, Hsi ED. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group study. *Ann Oncol* 21(6):1196-1202, 2010. PMID: 19875761; PMCID: PMC2875547
  92. Hatton BA, Villavicencio EH, Pritchard J, **LeBlanc M**, Hansen S, Ulrich M, Ditzler S, Pullar B, Stroud MR, Olson JM. Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. *Oncogene* 29(26):3865-3872, 2010. PMID: 20440271, PMCID: PMC2896441
  93. Kooperberg C, **LeBlanc M**, Obenchain V. Risk prediction using genome-wide association studies. *Gen Epidemiol* 34(7):643-652, 2010. PMID: 20842684. PMCID: PMC2964405
  94. **LeBlanc M**, Kooperberg C. Boosting predictions of treatment success. *Proc Natl Acad Sci U S A* 107(31):13559-13560, 2010. PMID: 20656935; PMCID: PMC2922272
  95. Arnold SM, Moon J, Williamson SK, Atkins JN, Ou S-HI, **LeBlanc M**, Urba SG. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. *Invest New Drugs* 29(2):352-359, 2011. PMID: 19937365, PMCID: PMC2892241
  96. Hoering A, **LeBlanc M**, Crowley J. Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents. *Clin Cancer Res* 17 (4):640-646, 2011. PMID: 21135145; PMCID: PMC4391513
  97. Rimsza LM, Unger JM, Tome ML, **LeBlanc M**. A Strategy for Full Interrogation of Prognostic Gene Expression Patterns: Exploring the Biology of Diffuse Large B Cell Lymphoma *PLoS One*. 2011; 6(8): e22267. Published online 2011 August 4. doi: 10.1371/journal.pone.0022267 PMCID: PMC3150354.
  98. Rubinstein L, **LeBlanc M**, Smith MA. More Randomization in Phase II Trials: Necessary but not Sufficient. *JNCI J Natl Cancer Inst*, 103(14): 1075-1077, 2011. PMID: 21709273; PMCID: PMC3139589
  99. Rudser K, Emerson S, **LeBlanc M**. Distribution-free Inference on Contrasts of Arbitrary Summary Measures of Survival, *Statistics in Medicine*, *Stat Med* 2012;31:1722-37. PMID:22362470
  100. Persky DO, Dornan D, Goldman B, Brazier R, Fisher R, **LeBlanc M**, Maloney DG, Press O, Miller T, Rimsza LM, Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone., *Haematologica* 2012 97: 937-942; PMID 22271896; PMCID: PMC3366663
  101. Schilsky RL, Doroshov JH, **LeBlanc M**, Conley BA. Development and use of integral assays in clinical trials. *Clin Cancer Res*. Mar 15;18(6):1540-6, 2012. PMID: 22422406; PMCID: PMC3307146
  102. **LeBlanc ML**, Tangen CM, Choosing Phase II Endpoints and Designs: Evaluating the possibilities. *Clin Cancer Res*. 2012 Mar 8. [Epub ahead of print] PMID: 22407830



103. Lee MJ, Hatton BA, Villavicencio EH, Khanna PC, Friedman S, Ditzler S, Pullar, Robison K, White K, Tunkey C, **LeBlanc M**, Randolph-Habecker J, Knoblaugh SE, Hansen S, Richards A, Wainwright B, McGovern K, Olson JM, The Hedgehog Pathway Inhibitor, Saridegib (IPI-926), Increases Lifespan in a Mouse Medulloblastoma Model, *PNAS*, May 15, 2012;109(20):7859-64. Epub 2012 May 1. PMID: 22550175; PMCID: PMC 3356655
104. Othus M, Barlogie B, **LeBlanc M**, Crowley J. Cure Models as a Useful Statistical Tool for Analyzing Survival, *Clin Cancer Res*. 2012 Jul 15;18(14):3731-6. Epub 2012 Jun 6. Dai JY, Kooperberg C, LeBlanc M, and Prentice, RL. Two-stage testing procedures with independent filtering for genome-wide gene-environment interaction. *Biometrika* 2012 99 (4): 929-944. PMID: 23843674; PMCID: PMC3629859
105. Pashova, H., **LeBlanc, M.** and Kooperberg, C. Boosting for detection of gene-environment interactions. *Stat Med* 2013;32:255-66. PMID:22764060; PMCID: PMC3561470
106. Stopeck AT, Unger JM, Rimsza LM, **LeBlanc M**, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP. A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. *Blood*. 2012 Aug 9;120(6):1210-7. doi: 10.1182/blood-2012-04-423079. Epub 2012 Jun 25. PMID: 22734071; PMCID: PMC3418716
107. Mahadevan D, Unger JM, Spier CM, Persky DO, Young F, **LeBlanc M**, Fisher RI, Miller TP. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. *Cancer*. 2013 Jan 15;119(2):371-9. doi: 10.1002/cncr.27733. Epub 2012 Jul 25. PMID: 22833464 [PubMed - indexed for MEDLINE]; PMCID: PMC3485430
108. Press OW, Unger JM, Rimsza LM, Friedberg JW, **LeBlanc M**, Czuczman MS, Kaminski M, Brazier RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016: *J Clin Oncol*. 2013 Jan 20;31(3):314-20. doi: 10.1200/JCO.2012.42.4101. Epub 2012 Dec 10. PMID: 23233710 [PubMed - indexed for MEDLINE]; PMCID: PMC3732010
109. Hoering A, Mitchell A, **LeBlanc M**, Crowley J. Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents: *Clin Trials*. 2013;10(3):422-9. doi: 10.1177/1740774513480961. Epub 2013 Mar 25. PMID: 23529697; PMCID: PMC3744092
110. Mehta S, Moon J, Hashmi M, **Leblanc M**, Huang CH, Rinehart E, Wolf GT, Urba SG, Banerjee SK, Williamson S. Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420: *Oncol Rep*. 2013 Jun;29(6):2095-100. doi: 10.3892/or.2013.2374. Epub 2013 Apr 2. PMID: 23563900; PMCID: PMC3694610
111. Redman MW, Goldman BH, **LeBlanc M**, Schott A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial: *Clin Cancer Res*. 2013 May 15;19(10):2646-56. doi: 10.1158/1078-0432.CCR-12-2939. PMID: 23669424; PMCID: PMC4131693
112. Press OW, Unger JM, Rimsza LM, Friedberg JW, **Leblanc ML**, Czuczman MS, Kaminski M, Brazier RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher R. A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma based on a Phase III Trial of CHOP-Rituximab vs CHOP + 131Iodine-Tositumomab: *Clin Cancer Res*. 2013 Oct 15. [Epub ahead of print] PMID: 24130072; PMCID: PMC3872052
113. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Miller TP, Tubbs RR, Marcellus D, Friedberg JW, Barton KP, Mills GM, **LeBlanc M**, Rimsza LM, Forman SJ, Fisher RI. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma: *N Engl J Med*. 2013 Oct 31;369(18):1681-90. doi: 10.1056/NEJMoa1301077. PMID: 24171516; PMCID: PMC3985418
114. Bernstein SH, Epner E, Unger JM, **Leblanc M**, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with

- previously untreated mantle cell lymphoma; SWOG 0213: *Ann Oncol.* 2013 Jun;24(6):1587-93. doi: 10.1093/annonc/mdt070. Epub 2013 Mar 15. PMID: 23504948; PMCID: PMC3660082
115. Unger JM, Barlow WE, Martin DP, Ramsey SD, **LeBlanc M**, Etzioni R, Hershman DL. Comparison of Survival Outcomes among Cancer Patients Treated In and Out of Clinical Trials, *JNCI*, 2014 Mar;106(3): dju002.doi:10.1093/jnci/dju002. PMID: 24627276; PMCID: PMC3982777
  116. Dey J, Dubuc AM, Pedro KD, Thirstrup D, Mecham B, Northcott PA, Wu X, Shih D, Tapscott SJ, **LeBlanc M**, Taylor MD, Olson JM. MyoD is a tumor suppressor gene in medulloblastoma. *Cancer Res.* 2013 Nov 15;73(22):6828-37. doi: 10.1158/0008-5472.CAN-13-0730-T. Epub 2013 Oct 3. PMID: 24092238; PMCID: PMC4014678
  117. Cook, James R, Goldman, Bryan, Tubbs, Raymond R, Rimsza, Lisa, **LeBlanc, Michael**, Stiff, Patrick, Fisher, Richard. Clinical Significance of MYC Expression and/or “High-grade” Morphology in Non-Burkitt, Diffuse Aggressive B-cell Lymphomas: A SWOG S9704 Correlative Study. *American Journal of Surgical Pathology*:April 2014 - Volume 38 - Issue 4 - p 494–501 doi: 10.1097/PAS.000000000000147. PMID: 24625415; PMCID: PMC3955880
  118. Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, **LeBlanc ML**, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. “Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.” *Am J Hematol.* 2014 Jun;89(6):639-45. doi: 10.1002/ajh.23709. Epub 2014 Apr 12. PMID: 24633940; PMCID: PMC4137041
  119. Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, et al. Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. *Clinical Cancer Research.* 2014;20:4210-7. PMID: 25125258; PMCID: PMC4135521
  120. Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, **LeBlanc M**, Ramsey SR. The diffusion of docetaxel in patients with metastatic prostate cancer. *J Natl Cancer Inst.* 2015;107(2). Epub 2014/12/30. doi: 10.1093/jnci/dju412. PMID: 25540245; PMCID: PMC4326312.
  121. Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea BD, Press OW, Constine LS, Barton KP, Friedberg JW, **LeBlanc M**, Fisher RI. Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. *Blood.* 2015;125(2):236-41. Epub 2014/11/15. doi: 10.1182/blood-2014-06-584623. PMID: 25395425; PMCID: PMC4287635.
  122. Friedberg JW, Unger JM, Burack WR, Gopal AK, Raju RN, Nademanee AP, Kaminski MS, Li H, Press OW, Miller TP, Fisher RI. R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433. *Br J Haematol.* 2014 Aug;166(3):382-9. doi: 10.1111/bjh.12906. Epub 2014 Apr 18. PMID: 24749780; PMCID: PMC4107050
  123. Philip PA, Chansky K, **LeBlanc M**, Rubinstein L, Seymour L, Ivy SP, Alberts SR, Catalano PJ, Crowley J. Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single-arm phase II trials. *Clin Cancer Res.* 2014 Aug 15;20(16):4176-85. doi: 10.1158/1078-0432.CCR-13-2024. Epub 2014 Jun 9. PMID: 24914040; PMCID: PMC4296727
  124. Herbst RS, Gandara DR, Hirsch FR, Redman MW, **LeBlanc M**, Mack PC, Schwartz LH, Vokes E, Ramalingam SS, Bradley JD, Sparks D, Zhou Y, Miwa C, Miller VA, Yelensky R, Li Y, Allen JD, Sigal EV, Wholley D, Sigman CC, Blumenthal GM, Malik S, Kelloff GJ, Abrams JS, Blanke CD, Papadimitrakopoulou VA. Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. *Clin Cancer Res.* 2015 Apr 1;21(7):1514-24. doi: 10.1158/1078-0432.CCR-13-3473. Epub 2015 Feb 13. PMID: 25680375; PMCID: PMC4654466
  125. Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, **LeBlanc M**, Cerhan JR, Novak A, Ansell SM. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular

- lymphoma. *Blood*. 2015;125(6):992-8. Epub 2014/11/26. doi: 10.1182/blood-2014-06-583369. PMID: 25422100; PMCID: PMC4319239.
126. Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L, **LeBlanc M**, Tilly H, Friedberg JW. Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. *J Clin Oncol*. 2015;33(13):1482-90. Epub 2015/04/01. doi: 10.1200/jco.2014.57.5092. PMID: 25823738; PMCID: PMC4404425.
  127. Barr PM, Li H, Spier C, Mahadevan D, **LeBlanc M**, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. *J Clin Oncol*. 2015;33(21):2399-404. Epub 2015/06/17. doi: 10.1200/jco.2014.60.6327. PubMed PMID: 26077240; PMCID: PMC4500834.
  128. Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF, Jr., Pozdnyakova O, Smith SM, **LeBlanc M**, Friedberg JW. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. *Br J Haematol*. 2015. Epub 2015/10/23. doi: 10.1111/bjh.13818. PMID: 26492567; **PMC4710555**
  129. **LeBlanc M**, Tangen C. Surrogates for Survival or Other End Points in Oncology. *JAMA Oncol*. 2015;1-2. Epub 2015/11/26. doi: 10.1001/jamaoncol.2015.4711. PMID: 26605695
  130. Dazard J-E, Choe M, **LeBlanc M**, Sunil Rao J.S, Cross-validation and Peeling Strategies for Survival Bump Hunting using Recursive Peeling Methods, *Statistical Methods and Data Analysis*, 2016 Feb;9(1):12-42. Epub 2016 Jan 22. PMID: 27034730
  131. Unger J, Barlow W, Ramsey S, **LeBlanc M**, Blanke C, Hershman D. The Scientific Impact of Positive and Negative Phase III Cancer Clinical Trials, *JAMA Oncology*, 2016 Mar 10. doi: 10.1001/jamaoncol.2015.6487; **PMC4945370**
  132. Puvvada SD, Stiff PJ, **LeBlanc M**, Cook JR, Couban S, Leonard JP, Kahl B, Marcellus D, Shea TC, Winter JN, Li H, Rimsza LM, Friedberg JW, Smith SM, Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. *Br. J Haematol*. 2016 Sep; 174(5):686-91. DOI: 10.1111/bjh.14100. Epub 2016 Apr 13. PMID: 27072903; **PMC in Process in PubMed**
  133. Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, **LeBlanc M**, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. *J Clin Oncol*. 2016 June 10;34(17):2020-7. doi: 10.1200/JCO.2015.63.1119. Epub 2016 Apr 11.
  134. Puvvada SD, Li H, Rimsza LM, Bernstein SH, Fisher RI, **LeBlanc M**, Schmelz M, Glinsmann-Gibson B, Miller TP, Maddox AM, Friedberg JW, Smith SM, Persky DO. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. *Leuk Lymphoma*. 2016 Oct;57(10):2359-69. doi: 10.3109/10428194.2015.1135431. Epub 2016 Jan 12. PMID: 26758422; **PMC in Process in PubMed**
  135. Stephens DM, Li H, **LeBlanc ML**, Puvvada SD, Persky D, Friedberg JW, Smith SM. Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. *J Clin Oncol*. 2016 Sep 1;34(25):2997-3004. doi: 10.1200/JCO.2015.65.4582. Epub 2016 Jul 5. PMID:27382104; **PMC PMC5012710**

b) Other Refereed Scholarly Publications and c) Books and Book Chapters

136. **LeBlanc M.** Tree-based tools for censored survival data, Proceedings of the XV International Biometrics Conference, pp. 123-138, 1990.
137. **LeBlanc M.** A stratification option for tree-based regression. Proceedings of the 23rd symposium on the interface between computing science and statistics. pp. 403-406, 1991.
138. Feld R, Sagman U, **LeBlanc M.** Staging, classification and prognostic factors for small cell lung cancer in lung cancer. Principles and Practice, Lippencott-Raven, 1995.
139. **LeBlanc M,** Crowley J. A review of tree-based prognostic models. Recent Advances in Clinical Trial Design and Analysis. Peter F. Thall (ed.), Kluwer Academic Publishers pp. 113-124, 1995.
140. Crowley J, **LeBlanc M,** Gentleman R, Salmon S. Exploratory methods in survival analysis. Hira Koul (ed). Analysis of Censored Data, IMS Lecture Notes-monograph Series pp. 55-78, 1996.
141. Miller T, Dahlberg S, Cassady J, Budd G, Spier C, Grogan T, Carlin S, Chase E, **LeBlanc M,** Fisher R. CHOP plus radiotherapy is superior to CHOP alone for adjuvant therapy of resected localized unfavorable non-Hodgkin's lymphoma: A Southwest Oncology Group study. Adjuvant Therapy of Cancer VIII, Lippincott-Raven, 1996.
142. Crowley J, **LeBlanc M,** Jacobson J, Salmon S. Some exploratory methods for survival data. In proceedings of the First Seattle Symposium in Biostatistics: Survival Analysis. DY Lin and T.R. Fleming, Eds. Springer-Verlag, New York pp. 199-230, 1997.
143. **LeBlanc M.** Tree-based methods for prognostic stratification. In: Handbook of Statistics in Clinical Oncology: Crowley, J.(ed) Marcel-Dekker; pp 457-472, 2001.
144. **LeBlanc M.** Regression Trees. In: Encyclopedia of Environmetrics, Abdel El-Shaarawi (ed), Walter Piegorsch (ed), Wiley. 1734-1738, 2002.
145. **LeBlanc M.** Tree structured methods. In: Encyclopedia of Environmetrics, Abdel El-Shaarawi (ed), Walter Piegorsch (ed), Wiley, 2242-2243, 2002.
146. Ruczinski I, Kooperberg C, **LeBlanc M.** Logic regression methods and software. In proceedings of the MRSI workshop, Workshop on nonlinear estimation and classification, Springer, 333-344, 2002.
147. Pauler DK, Hardin J, Faulkner J, **LeBlanc M,** Crowley JJ. Survival analysis with gene expression arrays. In: Handbook of Statistics, CR Rao (ed), N Balakrishnan (ed), Amsterdam: Elsevier Science, 675-687, 2004.
148. **LeBlanc M,** Rasmussen E, Crowley J: Constructing Prognostic Groups by Tree-based Partitioning and Peeling Methods. In: Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology (ed 2). New York, Marcel Dekker, Inc, 2006
149. Anderson G, **LeBlanc M,** Liu PY, Crowley J: On Use of Covariates in Randomization and Analysis of Clinical Trials. In: Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology (ed 2). New York, Marcel Dekker, Inc., 2006
150. Liu PY, Moon J, **LeBlanc M:** Phase II Selection Designs. In: Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology (ed 2). New York, Marcel Dekker, Inc., 2006
151. Kooperberg C, **LeBlanc M:** Multivariate Nonparametric Regression. In: Ronghui X, Xiachyn L (eds): High-Dimensional Data Analysis in Cancer Research. Springer, 35-58, 2009.
152. Liu PY, Moon J, **LeBlanc M:** Phase II Selection Designs. In: Crowley J, Ankerst DP (eds): Handbook of Statistics in Clinical Oncology (ed 2). Boca Raton, Chapman and Hall/CRC, 155-166, 2006.
153. Kooperberg C, **LeBlanc M:** Multivariate Nonparametric Regression. In: Ronghui X, Xiachun L (eds): High-Dimensional Data Analysis in Cancer Research. Springer, 35-58, 2009.
154. Liu PY, Moon J, **LeBlanc M.** Randomized Phase II Selection Designs, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Hoering and John Crowley, Chapman and Hall/CRC, 151-162, 2012
155. Anderson G, **LeBlanc M,** Liu PY, Crowley J. On Use of Covariates in Randomization and Analysis of Clinical Trials, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Hoering and John Crowley Chapman and Hall/CRC, 185-198, 2012
156. Hoering A, **LeBlanc M,** Crowley J. Phase III trials for Targeted Agents, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Hoering and John Crowley, Chapman and Hall/CRC, 251-264, 2012
157. **LeBlanc M,** Crowley J. Prognostic Groups by Tree-based Partitioning and Data Refinement Methods, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Crowley and John Hoering Chapman and Hall/CRC, 505-528, 2012

158. **LeBlanc M**, Rankin C, Crowley J. Phase II with Multiple Subgroups: designs incorporating disease subtype or genetic heterogeneity, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Crowley and John Hoering Chapman and Hall/CRC, 163-174, 2012
159. **LeBlanc M**, Goldman B, Kooperberg, C. Methods for SNP Regression Analysis in Clinical Studies: Selection, Shrinkage and Logic, Handbook of Statistics in Clinical Oncology, Third Edition, Antje Crowley and John Hoering Chapman and Hall/CRC, 591-564, 2012
160. **LeBlanc M**. Regression Trees. In: Encyclopedia of Environmetrics, Brian Everett, Wiley StatsRef-Statistics Reference Online. (ed), Wiley. To Appear 2015.
161. Hoering A, **LeBlanc M**, Crowley J. Phase III Randomized Clinical Trials Using Biomarkers: Comparison of Randomized Clinical Trial Designs for Targeted Agents, in Design and Analysis of Clinical Trials for Predictive Medicine, Chapman and Hall/CRC, 147-164, 2015.
162. Hoering A, **LeBlanc M**, Crowley J. Comparison of Randomized Clinical Trial Designs for Targeted Agents, in Design and Analysis of Clinical Trials for Predictive Medicine, Talyor and Francis Group LLC, Boca Raton, FL 33487, 2015.

d) Other Non-Refereed Published Scholarly Publications – not applicable

## 8. Patents and Other Intellectual Property: Not applicable

## 9. Funding History

### a) Funded Projects

P01 CA53996 (Prentice/Hsu) Statistical Methods for Medical Studies	07/15/2011 – 06/30/2017 (NCE)
R01 CA155360 (Olson) Infant and Toddler Brain Tumors	06/07/2011 – 03/31/2016
R01 HL114901 (Dai) Statistical Inference In Genome-Wide Association And Sequencing Studies	07/15/2012 – 06/30/2018
UM1 CA182883 (Tangen) PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research	09/20/2013 – 08/31/2018
U10 CA180819 ( LeBlanc) SWOG Statistics and Data Management Center (SDMC)	04/17/2014 – 02/28/2019
UG1CA189974 (Tangen) SWOG NCORP Research Base	08/01/2014 – 07/31/2019
SWOG-CTI-S1400 (LeBlanc) Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer	08/01/2014 – 07/31/2019
U24CA196175 (Ramirez) SWOG Biospecimen Bank	04/23/2015 – 03/31/2020
R01 HG006124 (Kooperberg) Adaptive Statistical Methods for Genetic Association Studies	03/01/2011 – 02/28/2015
R01 CA90998 (LeBlanc) Statistical Methods for Clinical Studies	08/05/2008 – 07/31/2012
U10 CA38926 (LeBlanc)	01/01/2010 – 12/31/2015

Southwest Oncology Group Statistical Center

**10. Public Health Practice Activities:** Not applicable

**11. Conferences and Symposiums**

International Biometric Conference, Invited: Lecture on exploratory survival analysis. Budapest, July 2-6, 1990. Tree-based tools for survival data.

Annual Meeting of the American Statistical Association, Boston, MA., August 9-11, 1992. Invited: Discussion of two papers on new methods for neural networks by Geoff Hinton and David Mackay.

Annual Meeting of the Canadian Statistical Association, Banff, Alberta, May 8-11, 1994. Invited: Adaptive Survival Models.

International Biometric Conference, Hamilton, Ontario, Canada, August 8-12, 1994. Invited: Discussion of two papers on generalized additive models.

Annual Meeting of the American Statistical Association, Toronto, Ontario, Canada, August 14-18, 1994. Invited: Tutorial on Tree-Based Methods for Survival Analysis.

Annual Meeting of the Biometric Society/WNAR, June 26-28, 1995. Invited: Lecture on Shrinkage Trees.

Annual Meeting of the American Statistical Association, Orlando, Florida, August 13-17, 1995. Invited: Lecture on Adaptive Regression Splines in the Cox model.

Annual Meeting of the Canadian Statistical Society, Waterloo, Ont, June 3-5, 1996. Invited: Some Exploratory Methods for Survival Data.

Annual Meeting of the Biometric Society/WNAR, June 24-26, 1996. Invited: Pruning and Shrinking Trees.

Annual Meeting of the American Statistical Association, Chicago, Illinois, August 5-7, 1996. Invited: Tutorial on Survival Trees.

Statistical Modeling of Discrete Data and Structures, Munich, October 24-26, 1996. Invited: Pruning and Shrinking Trees.

Annual Meeting of the Biometric Society/ENAR, Pittsburgh, PA, March 29-April 1, 1998. Invited: Discussion of Exploratory Analysis Using Classification Trees.

The World of Genomics-Medical Applications and Social Implications, Santander, Spain, August 3-7, 1998. Invited:

1. Molecular Clinical and Epidemiological Studies: Design and Data Analysis
2. New Biostatistical Methods for Marker Analysis.

Current Advances and Trends in Nonparametric Statistics, Crete, Greece, July 15-19, 2002. Invited: Partitioning, Peeling, and Logic for Prognostic Groups.

Annual Meeting of the Biometric Society/WNAR, Golden, Colorado, June 23-25, 2003. Invited: Directed Indices for Exploring Gene Expression.

US-Japan Biostatistics Workshop, Kobe, Japan, September 26, 2003. Invited: Gene Exploration and Correlation: Applications to Lymphoma.

Fifth Biennial International Conference on Statistics, Probability and Related Areas, Athens, Georgia, May 14-16, 2004. Invited: Extreme Models.

Second US-Japan Biostatistics Workshop, Seattle, WA, September 23-24, 2004. Invited: Extreme Regression and Other New Methods for Prognostic Analysis.

Annual Meeting of the American Statistical Association, Minneapolis, MN, August 7-11, 2005. Invited: Extreme Regression Models for Prognosis.

US-Japan Biostatistics Workshop, Kyoto, Japan, October 7, 2005. Invited: Prognostic Modeling Rules.

Cooperative Group Statisticians Meeting, Seattle, WA, August 6, 2006: Interim Analyses with Early Endpoints.

Enhancing Development of Genome-wide Association Methods (ENDGAME) Meeting, Herndon, VA, December 1, 2006. Subgroup Weighted Association Tests.

Annual Meeting of the American Statistical Association, Salt Lake City, UT, July 29 – August 2, 2007. Subgroup Weighted Association Tests.

American Society of Clinical Oncology (ASCO), Phase II Development of Novel Therapeutics in Lymphoma, Aspen, CO, September 18-19, 2007. Invited: Traditional Randomized and Screening Phase II Designs.

Annual INFORMS Meeting, Seattle, WA, November 4 – 7, 2007. Invited: New Developments in Tree-based Methods with Applications to Targeted Medicine.

Recent Advances in Biological Process Workshop, Fred Hutchinson Cancer Research Center, Seattle WA, December 1-2, 2008. Invited: Using Interactions to Find Main Effects in Genome-wide Association Studies.

The International Kurume Symposium on Biostatistics, Fukuoka, Japan, January 30-31, 2009. Invited: New Strategies for Constructing Prognostic and Varying Treatment Efficacy Models for Survival Data: Applications to Cancer Clinical Trials.

Biostatistics Workshop in Cancer Research, Toronto, Canada, July 24-26, 2009. Invited: Targeted Subgroup Effect Modeling.

Interface 2010: Computational Statistics and Human Behavior, Seattle, Washington, June 16-18, 2010. Invited: Emerging Data from Clinical Trials.

ICSA 2010 Applied Statistics Symposium, Indianapolis, Indiana, June 20-23, 2010. Invited: Using Models to Assess and Harness Interactions in High Dimensional Genomic Data.

Investigational Drug Steering Committee (IDSC) Meeting, March 15, 2011. Rockville, MD. Invited: Historical Controls Database : Pancreatic Cancer and Advanced NSCLC.

Annual Biostatistics Research Day, Toronto CA. April 29, 2011. Invited: Assessing Interactions and Associations in Modern Clinical Trials.

Society of Clinical Trials Meeting, Vancouver CA. May 16-19, 2011. Invited: Soft Enrichment: Using Phase II Data for Designing Targeted Groups.

NCI Workshop on Criteria for Use of 'Omics-Based Predictors in Clinical Trials. June 23-24, 2011, Bethesda, MD. Invited: Blinded Clinical Validations – Role of Honest Broker.

Annual Meeting of the American Statistical Association, Miami Beach, FL, Aug 1-4, 2011. Invited: Using Interactions in Moderately Sized Randomized Studies.

Annual Meeting of the Biometric Society/ENAR, Washington DC, March 31-April 3, 2012. Invited: Validating Clinical Performance of Predictors.

International Biometric Conference, Florence, IT, July 7-11, 2014. Invited: Flexible subgroup treatment interaction modeling

Annual Meeting of the American Statistical Association, Boston MA, Aug 2-7, 2014. Invited: A Smooth Basis for Prognostic Rules

Statistical Issues in Biomarker and drug development, Fields Institute, Toronto, November 9-11, 2014, Invited: Some experience with biomarker driven cancer clinical trials

SWOG Plenary I, San Francisco CA, April 30, 2015, Invited: Statistics for TM studies and bucket trials.

Annual Meeting of The Canadian Statistical Society, Halifax NS, June 15-17, 2015, Invited: Refinement Rules for Prognosis and Enhanced Treatment Effect Subgroups

Annual Meeting of the American Statistical Association, Seattle WA, Aug 8-13, 2015, Some experience with biomarker driven cancer clinical trials

**Society of Clinical Trials Meeting, Montreal, CA, May 15-18, 2016. Invited: Statistical Models in immuno-oncology**

## 12. University Services

### University and Fred Hutchinson Cancer Research Center Committees:

MRC self-managed discussion group for young investigators, University of Toronto, 1992.

Departmental committee for input to the Leyerle Commission, Department of Preventive Medicine and Biostatistics University of Toronto, 1992-93.

Member of computer committee, Department of Statistics, University of Toronto, 1992-94.

Member of the statistical consulting committee, Department of Statistics, 1993.

Member of the strategic planning committee, Department of Preventive Medicine and Biostatistics, University of Toronto, 1993.

Member of the curriculum committee, Department of Biostatistics, University of Washington, 1997-2000.  
 Member of statistical theory exam committee, Department of Biostatistics, University of Washington, 1998, 2000, 2003.  
 Member of admissions committee, Department of Biostatistics, University of Washington, 1998-2006.  
 Member of faculty Senate, University of Washington, 2001- 2003.  
 Member of faculty search and promotion committees, Fred Hutchinson Cancer Research Center, 1997, 2000-present.

**13. Professionally-Related Community Service:** Not applicable

#### **14. Other Pertinent Information**

##### Special Fields of Interest:

Development and application of adaptive regression techniques.  
 Tree-based methods for regression and exploratory survival analysis.  
 Statistical methods for clinical trials.  
 Interface of genomics and clinical trials.

#### **15. Teaching History:**

Teaching Assistant, University of Waterloo, 1983-84.  
 Teaching Assistant, University of Washington, 1987-88.  
 Applied statistical training of biostatistics students through Research Services Unit (approximately 25 projects per year), 1990-94.  
 Survival Analysis (currently CHL 3118) (with John McLaughlin), 1991.  
 Laboratory Course in the Statistical Design and Analysis (with Paul Corey and Rob Tibshirani), CHL4507, 1990-95.  
 Laboratory Course in the Statistical Design and Analysis (with Paul Corey and Rob Tibshirani), CHL4507, 1991.  
 Survival Analysis, CHL 4515, 1992.  
 Prospective Studies and Survival Analysis, CHL3118 (with John McLaughlin), 1992.  
 Laboratory Course in the Statistical Design and Analysis (with Paul Corey and Rob Tibshirani), CHL4507, 1993.  
 Survival Analysis, CHL 4515, 1993.  
 Prospective Studies and Survival Analysis, CHL3118 (with John McLaughlin), 1994.  
 Survival Analysis, CHL 4515, 1994.  
 Laboratory Course in the Statistical Design and Analysis (with Paul Corey and Mike Escobar), CHL4507, 1994.  
 Biostat 580, Organized Seminars in Biostatistics, 1996.  
 Biostat 578, Special Topics: Non-parametric Estimation using Smoothers, Trees and Splines (with Charles Kooperberg), 1997.  
 SWOG, Young Investigators Course, 2002-present.

#### **16. Advising and Formal Mentoring**

##### Graduate Student Supervision (committee member):

Susan Kirkland (Ph.D. Epidemiology),  
 Lillian Yuan (M.Sc. Epidemiology),  
 Paige Bracci (M.Sc. Biostatistics),  
 Carmen Mueller (M.Sc. Epidemiology),  
 Peggy McDonough (Ph.D. Behavioral Science),  
 Martin Tammemagi (M.Sc. Epidemiology),



Stephani Strathdee (Ph.D. Epidemiology),  
Julie Arnold (M.Sc. Epidemiology),  
Leslie Beck (M.Sc. Epidemiology),  
George Tomlinson (M.Sc. Biostatistics),  
Margareth Kasendra (M.Sc. Epidemiology),  
Elizabeth Rea (M.Sc. Epidemiology),  
Xiaoyan Zhou (M.Sc. Epidemiology),  
Jennifer Payne (Ph.D. Epidemiology).  
Sunil Rao (Ph.D. Biostatistics),  
Kiros Berhane (Ph.D. Biostatistics),  
Wendy Lou (Ph.D. Biostatistics),  
Peter Gilbert (Ph.D. Biostatistics),  
James Lymph (Ph.D. Biostatistics),  
Adam Olshen (Ph.D. Biostatistics),  
Robyn McClelland (Ph.D. Biostatistics),  
Debashis Ghosh (Ph.D. Biostatistics).  
Kim Young (M.S. Biostatistics)  
Mose Andre (M.S. Biostatistics)  
Joseph Unger (PhD Health Services)  
Chao-Kang J. Liang (PhD, Biostatistics)  
David Prince (PhD, Biostatistics)

Primary/Joint Supervision:

Wendy Lou (M.Sc. Biostatistics) (with Paul Cory),  
Mohamed Abdoell (M.Sc. Biostatistics),  
Shi-Yun Shen (Ph.D. Biostatistics) (with Rob Tibshirani),  
Elizabeth Kexel (M.S. Biostatistics),  
Ingo Ruczinski (Ph.D. Statistics) (with Charles Kooperberg),  
Martha Nason (Ph.D. Biostatistics) (with Scott Emerson).  
James Dai (Ph.D. Biostatistics) (with Charles Kooperberg)  
Kyle Rudser (Ph.D. Biostatistics) (with Scott Emerson).  
Hristina Pashova (Ph.D. Biostatistics) (with Charles Kooperberg)